LIFE News and Press, aTyr Pharma Inc. From 08/11/22

SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced t...

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter 2022 financ...

Super Micro Computer ( SMCI ) +20% on better-than-expected Q4 prelim results. ToughBuilt Industries ( TBLT ) +16% . MoonLake Immunotherapeutics ( MLTX ) +14% . Visionary Education Technology Holdings ( VEDU ) +12% . Olema Pharmaceuti...

Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO, Ju...

SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that Leslie A. Nangle, Ph.D., Vice President, ...

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. Shukla, M.D., M.S., President and C...

The following slide deck was published by aTyr Pharma, Inc. in conjunction with this event. For further details see: aTyr Pharma (LIFE) Investor presentations - Slideshow

The following slide deck was published by aTyr Pharma, Inc. in conjunction with this event. For further details see: aTyr Pharma ATS Conference Presentation May 2022

aTyr Pharma (NASDAQ:LIFE) stock fell ~3% after Piper Sandler lowered its target on the company's shares to $11 from $19. Piper Sandler analyst maintained an Overweight rating on the stock after aTyr presented data from a phase 1b/2a trial of efzofitimod in pulmonary sarcoidosis (PS) ...

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarco...